Olga Frankfurt
Overview
Explore the profile of Olga Frankfurt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
64
Citations
1979
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Altman J, Zuckerman T, Koprivnikar J, McCloskey J, Kota V, Keng M, et al.
Blood Adv
. 2023 Oct;
7(24):7494-7500.
PMID: 37903324
High-dose cytarabine is associated with gastrointestinal and cerebellar toxicity, precluding its use for older or unfit patients with acute myeloid leukemia (AML). Aspacytarabine, an inactive prodrug of cytarabine, was evaluated...
2.
Lin C, Schwarzbach A, Sanz J, Montesinos P, Stiff P, Parikh S, et al.
Transplant Cell Ther
. 2023 Feb;
29(5):338.e1-338.e6.
PMID: 36775201
Omidubicel is an umbilical cord blood (UCB)-derived ex vivo-expanded cellular therapy product that has demonstrated faster engraftment and fewer infections compared with unmanipulated UCB in allogeneic hematopoietic cell transplantation. Although...
3.
Ma S, Rosen S, Winqvist M, Frankfurt O, Winter J, Gordon L, et al.
Leuk Res
. 2022 Sep;
122:106945.
PMID: 36115087
This phase 2 study describes long-term clinical and immunological effects of fixed-duration ofatumumab (anti-CD20) and alemtuzumab (anti-CD52) combination immunotherapy in 52 patients with previously untreated CLL. The median age was...
4.
de Botton S, Montesinos P, Schuh A, Papayannidis C, Vyas P, Wei A, et al.
Blood
. 2022 Jun;
141(2):156-167.
PMID: 35714312
This open-label, randomized, phase 3 trial (NCT02577406) compared enasidenib, an oral IDH2 (isocitrate dehydrogenase 2) inhibitor, with conventional care regimens (CCRs) in patients aged ≥60 years with late-stage, mutant-IDH2 acute...
5.
Numan Y, Rahman Z, Grenet J, Boisclair S, Bewersdorf J, Collins C, et al.
Am J Hematol
. 2022 Jan;
97(3):322-328.
PMID: 34981560
Gilteritinib is approved for the treatment of relapsed/refractory (R/R) acute myeloid leukemia (AML) with an FLT3-mutation (FLT3 ). However, the gilteritinib phase 3 ADMIRAL study (Perl et al NEJM 2019)...
6.
Zeidner J, Lin T, Vigil C, Fine G, Yair Levy M, Nazha A, et al.
Blood Cancer J
. 2021 Oct;
11(10):175.
PMID: 34718324
No abstract available.
7.
Gao J, Gurbuxani S, Zak T, Kocherginsky M, Ji P, Wehbe F, et al.
Genes Chromosomes Cancer
. 2021 Oct;
61(2):71-80.
PMID: 34668265
MECOM rearrangements are recurrent in myeloid neoplasms and associated with poor prognosis. However, only inv(3)(q21q26.2) and t(3;3)(q21;q26.2), the classic MECOM rearrangements resulting in RPN1-MECOM rearrangement with Mecom overexpression and GATA2...
8.
Sweet K, Bhatnagar B, Dohner H, Donnellan W, Frankfurt O, Heuser M, et al.
Leuk Lymphoma
. 2021 Jul;
62(13):3192-3203.
PMID: 34323164
Selinexor, a selective inhibitor of nuclear export, has demonstrated promising activity in patients with acute myeloid leukemia (AML). This randomized, phase II study evaluated selinexor 60 mg twice weekly ( ...
9.
Gao J, Fu L, Lu X, Sukhanova M, Frankfurt O, Mohtashamian A, et al.
Leuk Lymphoma
. 2021 Jul;
62(13):3304-3307.
PMID: 34261406
No abstract available.
10.
Seltzer J, Frankfurt O, Kyriacou D
Acad Emerg Med
. 2021 Jul;
29(1):73-82.
PMID: 34245642
Background: Earlier initial antibiotic treatment for febrile neutropenia is associated with improved clinical outcomes. This study was conducted to evaluate the association of an emergency department (ED) intervention protocol with...